Tau protein abnormalities associated with the progression of alzheimer disease type dementia

Neurobiology of Aging

Volumn 28, Issue 1, 2007, Pages 1-7

  Haroutunian, V ^a,b   Davies, P ^c   Vianna, C ^c   Buxbaum, J D ^a   Purohit, D P ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Alzheimer disease; Dementia; Neurofibrillary tangles; Tau

Indexed keywords

TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CADAVER; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRONTAL CORTEX; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; PHOSPHORYLATION; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; BRAIN; BRAIN CHEMISTRY; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; TAU PROTEINS;

EID: 33751245561     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2005.11.001     Document Type: Article

References (57)

1. Consensus report of the Working Group. Molecular and biochemical markers of Alzheimer's disease. The Ronald and Nancy Reagan research institute of the Alzheimer's association and the national institute on aging working group. Neurobiol Aging 19 (1998) 109-116
2. Ball M. Neuronal loss, neurofibrillary tangles and granulovacuolar degeneration in the hippocampus with ageing and dementia. Acta Neuropathol (Berl) 37 (1977) 111-118
3. Bennett D.A., Schneider J.A., Wilson R.S., Bienias J.L., and Arnold S.E. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol 61 (2004) 378-384
4. Binder L.I., Guillozet-Bongaarts A.L., Garcia-Sierra F., and Berry R.W. Tau, tangles and Alzheimer's disease. Biochim Biophys Acta 1739 (2005) 216-223
5. Braak H., and Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 82 (1991) 239-259
6. Braak H., and Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 16 (1995) 271-278
7. Braak H., and Braak E. Evolution of the neuropathology of Alzheimer's disease. Acta Neurol Scand Suppl 165 (1996) 3-12
8. Braak H., Braak E., Bohl J., and Reintjes R. Age, neurofibrillary changes, a beta-amyloid and the onset of Alzheimer's disease. Neurosci Lett 210 (1996) 87-90
9. Buee-Scherrer V., Condamines O., Mourton-Gilles C., Jakes R., Goedert M., Pau B., et al. AD2, a phosphorylation-dependent monoclonal antibody directed against tau proteins found in Alzheimer's disease. Brain Res Mol Brain Res. 39 (1996) 79-88
10. Bussiere T., Gold G., Kovari E., Giannakopoulos P., Bouras C., Perl D.P., et al. Stereologic analysis of neurofibrillary tangle formation in prefrontal cortex area 9 in aging and Alzheimer's disease. Neuroscience 117 (2003) 577-592
11. Bussiere T., Giannakopoulos P., Bouras C., Perl D.P., Morrison J.H., and Hof P.R. Progressive degeneration of non-phosphorylated neurofilament protein-enriched pyramidal neurons predicts cognitive impairment in Alzheimer's disease: stereologic analysis of prefrontal cortex area 9. J Comp Neurol 463 (2003) 281-302
12. Carmel G., Mager E.M., Binder L.I., and Kuret J. The structural basis of monoclonal antibody Alz50's selectivity for Alzheimer's disease pathology. J Biol Chem 271 (1996) 32789-32795
13. Damasio H., and Damasio A.R. In: Damasio H., and Damasio A.R. (Eds). Appendix in lesion analysis in neuropsychology (1989), Oxford University Press, New York
14. Davies P., Ghanbari H., Issacs A., Dickson D.W., Mattiace L.A., Rosado M., et al. TG3: a better antibody than ALZ-50 for the visualization of Alzheimer-type neuronal pathology. Soc Neurosci Abstracts 19 (1993) 670-673
15. Davis K.L., Mohs R.C., Marin D.B., Purohit D.P., Perl D.P., Lantz M., et al. Cholinergic markers are not decreased in early Alzheimer's disease. JAMA 281 (1999) 1401-1406
16. Dickson D.W., Crystal H.A., Bevona C., Honer W., Vincent I., and Davies P. Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol Aging 16 (1995) 285-298
17. Folstein M., Folstein S., and McHugh P. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiat Res 12 (1975) 189-198
18. Garcia-Sierra F., Ghoshal N., Quinn B., Berry R.W., and Binder L.I. Conformational changes and truncation of tau protein during tangle evolution in Alzheimer's disease. J Alzheimer's Dis 5 (2003) 65-77
19. Ghoshal N., Garcia-Sierra F., Wuu J., Leurgans S., Bennett D.A., Berry R.W., et al. Tau conformational changes correspond to impairments of episodic memory in mild cognitive impairment and Alzheimer's disease. Exp Neurol 177 (2002) 475-493
20. Greenberg S.G., Davies P., Schein J.D., and Binder L.I. Hydrofluoric acid-treated tau PHF proteins display the same biochemical properties as normal tau. J Biol Chem 267 (1992) 564-569
21. Haroutunian V., Perl D.P., Purohit D.P., Marin D.B., Khan K., Lantz M., et al. Regional distribution of neuritic plaques in non-demented elderly and cases of very mild Alzheimer's disease. Arch Neurol 55 (1998) 1185-1191
22. Haroutunian V., Purohit D.P., Perl D.P., Marin D.B., Khan K., Lantz M., et al. Neurofibrillary tangles in nondemented elderly and very mild Alzheimer's disease. Arch Neurol 57 (1999) 713-718
23. Holzer M., Holzapfel H.P., Zedlick D., Bruckner M.K., and Arendt T. Abnormally phosphorylated tau protein in Alzheimer's disease: heterogeneity of individual regional distribution and relationship to clinical severity. Neuroscience 63 (1994) 499-516
24. Honer W.G., Dickson D.W., Gleeson J., and Davies P. Regional synaptic pathology in Alzheimer's disease. Neurobiol Aging 13 (1992) 375-382
25. Honer W.G., Kaufmann C.A., and Davies P. Characterization of a synaptic antigen of interest in neuropsychiatric illness. Biol Psychiatry 31 (1992) 147-158
26. Hughes C.P., Berg L., Danziger W.L., Coben L.A., and Martin R.L. A new clinical scale for the staging of dementia. B J Psych 140 (1982) 566-572
27. Hyman B.T. The neuropathological diagnosis of Alzheimer's disease: clinical-pathological studies. Neurobiol Aging 18 (1997) S27-S32
28. Hyman B.T., Van Hoesen G.W., Wolozin B.L., Davies P., Kromer L.J., and Damasio A.R. Alz-50 antibody recognizes Alzheimer-related neuronal changes. Ann Neurol 23 (1988) 371-379
29. Iqbal K., Alonso A.C., Chen S., Chohan M.O., El Akkad E., Gong C.X., et al. Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 1739 (2005) 198-210
30. Ishizawa T., Mattila P., Davies P., Wang D., and Dickson D.W. Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol 62 (2003) 389-397
31. Jicha G.A., Berenfeld B., and Davies P. Sequence requirements for formation of conformational variants of tau similar to those found in Alzheimer's disease. J Neurosci Res 55 (1999) 713-723
32. Jicha G.A., Bowser R., Kazam I.G., and Davies P. Alz-50 and MC-1, a new monoclonal antibody raised to paired-helical filaments, recognize conformational epitopes on recombinant tau. J Neurosci Res 48 (1997) 128-132
33. Jicha G.A., Lane E., Vincent I., Otvos L.J., Hoffmann R., and Davies P. A conformation- and phosphorylation- dependent antibody recognizing the paired-helical filaments of Alzheimer's disease. J Neurochem 69 (1997) 2087-2095
34. Knopman D.S., Parisi J.E., Salviati A., Floriach-Robert M., Boeve B.F., Ivnik R.J., et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol 62 (2003) 1087-1095
35. Ksiezak-Reding H., Leibowitz R.L., Bowser R., and Davies P. Binding of Alz 50 depends on Phe8 in tau synthetic peptides and varies between native and denatured tau proteins. Brain Res 697 (1995) 63-75
36. Liu W.K., Dickson D.W., and Yen S.H. Amino acid residues 226-240 of tau, which encompass the first Lys-Ser-Pro site of tau, are partially phosphorylated in Alzheimer paired-helical filament-tau. J Neurochem 62 (2003) 1055-1061
37. Liu W.K., and Yen S.H. The state of phosphorylation of normal adult brain tau, fetal tau and tau from Alzheimer paired-helical filaments at amino acid residue Ser 262. J Neurochem 66 (1996) 1131-1139
38. Mandelkow E.M., and Mandelkow E. Tau as a marker for Alzheimer's disease. Trends Biochem Sci 18 (1993) 480-483
39. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41 (1991) 479-486
40. Mitchell T.W., Mufson E.J., Schneider J.A., Cochran E.J., Nissanov J., Han L.Y., et al. Parahippocampal tau pathology in healthy aging, mild cognitive impairment and early Alzheimer's disease. Ann Neurol 51 (2002) 182-189
41. Moossy J., Zubenko G.S., Martinez A.J., and Rao G.R. Bilateral symmetry of morphologic lesions in Alzheimer's disease. Arch Neurol 45 (1988) 251-254
42. Morris J.C. The clinical dementia rating (CDR): current version and scoring rules. Neurology 43 (1993) 2412-2414
43. Morrison J.H., and Hof P.R. Selective vulnerability of corticocortical and hippocampal circuits in aging and Alzheimer's disease. Prog Brain Res 136 (2002) 467-486
44. Murayama S., and Saito Y. Neuropathological diagnostic criteria for Alzheimer's disease. Neuropathology 24 (2004) 254-260
45. Nakano H., Kobayashi K., Sugimori K., Shimazaki M., Miyazu K., Hayashi M., et al. Regional analysis of differently phosphorylated tau proteins in brains from patients with Alzheimer's disease. Dement Geriatr Cogn Disord 17 (2004) 122-131
46. Näslund J., Haroutunian V., Mohs R., Davis K.L., Davies P., Greengard P., et al. Elevated amyloid b-peptides in brain: correlation with cognitive decline. JAMA 283 (2000) 1571-1577
47. Nielson K.A., Cummings B.J., and Cotman C.W. Constructional apraxia in Alzheimer's disease correlates with neuritic neuropathology in occipital cortex. Brain Res 741 (1996) 284-293
48. Rogers J., and Morrison J.H. Quantitative morphology and regional and laminar distribution of senile plaques in Alzheimer's disease. J Neurosci 5 (1985) 2801-2808
49. Terry R.D. Tangles precede plaques, but don't cause them. Neurobiol Aging 25 (2004) 741-742
50. Tiraboschi P., Hansen L.A., Thal L.J., and Corey-Bloom J. The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology 62 (2004) 1984-1989
51. Tomlinson B.E., Blessed G., and Roth M. Observations on the brains of non-demented old people. J Neurol Sci 7 (1968) 331-356
52. Tomlinson B.E., Blessed G., and Roth M. Observations on the brains of demented old people. J Neurol Sci 11 (1970) 205-242
53. Uboga N.V., and Price J.L. Formation of diffuse and fibrillar tangles in aging and early Alzheimer's disease. Neurobiol Aging 21 (2000) 1-10
54. Weaver C.L., Espinoza M., Kress Y., and Davies P. Conformational change as one of the earliest alterations of tau in Alzheimer's disease. Neurobiol Aging 21 (2000) 719-727
55. Wolozin B., and Davies P. Alzheimer-related neuronal protein A68: specificity and distribution. Ann Neurol 22 (1987) 521-526
56. Wolozin B., Scicutella A., and Davies P. Reexpression of a developmentally regulated antigen in down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 85 (1988) 6202-6206
57. Zubenko G.S., Moossy J., Hanin I., Martinez A.J., Rao G.R., and Kopp U. Bilateral symmetry of cholinergic deficits in Alzheimer's disease. Arch Neurol 45 (1988) 255-259